Mirati Therapeutics price target raised to $62 from $35 at Oppenheimer. Oppenheimer analyst Leah Rush Cann raised her price target for Mirati Therapeutics to $62 from $35 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.